Phase II Study of Carboplatin and Vinorelbine i.v. (Day 1) and Orally (Day 8) for Malignant Pleural Mesothelioma
Chemotherapy with carboplatin i.v. day one in each cycle Vinorelbine i.v. day one, and
orally day 8 in each cycle, repeat new cycle every 3 weeks. Total of 6 cycles.
Endpoint is response rate, secondary endpoints survival and toxicity.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Jens B Sorensen, MD
Dept. Oncology, Rigshospitalet
Denmark: National Board of Health
MPM phase II Carbo/VNB